Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Novel therapies for children with severe asthma
Top Ten Searches
hla beta 2 probiotics hypo allergenic scid urticaria aeroallergens asthma angioedema hivYour Article Summary
See Latest ArticlesTimed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: A chemotherapy dose-ranging factorial study of safety and immune activation
Journal of Clinical Oncology, 10/08/09
Emens LA et al. – First, immunotherapy with an allogeneic, HER2-positive, GM-CSF–secreting breast tumor vaccine alone or with CY and DOX is safe and induces HER2-specific immunity in patients with metastatic breast cancer. Second, the immunomodulatory activity of low-dose CY has a narrow therapeutic window, with an optimal dose not exceeding 200 mg/m2. Third, factorial designs provide an opportunity to identify the most active combination of interacting drugs in patients. Further investigation of the impact of chemotherapy on vaccine-induced immunity is warranted.
Methods- Conducted a 3 x 3 factorial (response surface) dose-ranging study of CY, DOX, and an HER2-positive, allogeneic, GM-CSF–secreting tumor vaccine in 28 patients with metastatic breast cancer
- Patients received 3 monthly immunizations, with a boost 6 to 8 mos from study entry
- Primary objectives included safety and determination of chemotherapy doses that maximize HER2-specific immunity
- 28 patients received at least 1immunization, and 16 patients received 4 immunizations
- HER2-specific delayed-type hypersensitivity developed in most patients who received vaccine alone or with 200 mg/m2 CY
- HER2-specific antibody responses were enhanced by 200 mg/m2 CY and 35 mg/m2 DOX, but higher CY doses suppressed immunity
- Analyses revealed CY at 200 mg/m2 and DOX at 35 mg/m2 is combination that produced highest antibody responses
Today in Breast...keeping you current
Receive free subspecialty "5-minute updates" via email
Co-expression of CD173 (H2) and CD174 (Lewis Y) with CD44 suggests that fucosylated histo-blood group antigens are markers of breast cancer-initiating cells
Virchows Archiv, 03/22/10
Cyclin D1/Cyclin-Dependent Kinase 4 Interacts with Filamin A and Affects the Migration and Invasion Potential of Breast Cancer Cells
Cancer Research, 03/22/10
Targeting Id1 and Id3 by a specific peptide aptamer induces E-box promoter activity, cell cycle arrest, and apoptosis in breast cancer cells
Breast Cancer Research and Treatment, 03/19/10
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Successful Triple Combination Therapy of Disseminated Absidia corymbifera Infection in an Adolescent With Osteosarcoma
Journal of Pediatric Hematology/Oncology, 03/22/10
Successful Treatment of Life-threatening Candida Peritonitis in a Child With Abdominal Non-Hodgkin Lymphoma Using Efungumab and Amphotericin B Colloid Dispersion
Journal of Pediatric Hematology/Oncology, 03/22/10
Biweekly vinorelbine and gemcitabine as second-line and beyond treatment in ovarian cancer
Cancer Chemotherapy and Pharmacology, 03/22/10
Article Search
Sponsor
Sponsor